The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $24.22

Today's change+0.24 +1.00%
Updated July 22 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $24.22

Today's change+0.24 +1.00%
Updated July 22 4:00 PM -4GMT. Delayed by at least 15 minutes.

Coherus BioSciences Inc up (U.S.)$0.24

Coherus BioSciences Inc closed up Friday by (U.S.)$0.24 or 1.00% to (U.S.)$24.22. Over the last five days, shares have gained 2.58% and 5.49% year to date. Shares have underperformed the S&P 500 by 38.22% during the last year.

Key company metrics

  • Open(U.S.) $24.19
  • Previous close(U.S.) $23.98
  • High(U.S.) $24.33
  • Low(U.S.) $23.16
  • Bid / Ask(U.S.) $15.18 / (U.S.) $25.99
  • YTD % change+5.49%
  • Volume330,840
  • Average volume (10-day)558,920
  • Average volume (1-month)419,848
  • Average volume (3-month)363,141
  • 52-week range(U.S.) $12.04 to (U.S.) $38.10
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$6.43
Updated July 22 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-679.52%

Although this company's net profit margin is negative, it is above the industry average and implies that Coherus BioSciences Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.24%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue121077
Total other revenue--------
Total revenue121077
Gross profit--------
Total cost of revenue--------
Total operating expense77627866
Selling / general / administrative1111109
Research & development65516857
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-64-52-71-59
Interest income (expense), net non-operating-1000
Gain (loss) on sale of assets--------
Other--------
Income before tax-66-53-71-59
Income after tax-66-53-71-59
Income tax, total0------
Net income-65-52-71-59
Total adjustments to net income--------
Net income before extra. items-65-52-71-59
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-65-52-71-59
Inc. avail. to common incl. extra. items-65-52-71-59
Diluted net income-65-52-71-59
Dilution adjustment--------
Diluted weighted average shares39393838
Diluted EPS excluding extraordinary itemsvalue per share-1.67-1.34-1.86-1.56
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.67-1.34-1.86-1.56